nodes	percent_of_prediction	percent_of_DWPC	metapath
Aprepitant—CYP3A7-CYP3A51P—Sorafenib—thyroid cancer	0.103	0.186	CbGbCtD
Aprepitant—CYP3A7—Sorafenib—thyroid cancer	0.103	0.186	CbGbCtD
Aprepitant—CYP3A5—Sorafenib—thyroid cancer	0.0775	0.14	CbGbCtD
Aprepitant—CYP2C19—Sorafenib—thyroid cancer	0.0625	0.113	CbGbCtD
Aprepitant—CYP1A2—Sorafenib—thyroid cancer	0.0577	0.104	CbGbCtD
Aprepitant—CYP2C9—Sorafenib—thyroid cancer	0.052	0.0937	CbGbCtD
Aprepitant—CYP3A4—Vandetanib—thyroid cancer	0.0502	0.0903	CbGbCtD
Aprepitant—CYP3A4—Sorafenib—thyroid cancer	0.0302	0.0545	CbGbCtD
Aprepitant—CYP3A4—Doxorubicin—thyroid cancer	0.0183	0.033	CbGbCtD
Aprepitant—TACR3—Peptide GPCRs—TSHR—thyroid cancer	0.00365	0.0604	CbGpPWpGaD
Aprepitant—TACR3—GPCR ligand binding—CALCB—thyroid cancer	0.00189	0.0313	CbGpPWpGaD
Aprepitant—TACR1—Peptide GPCRs—TSHR—thyroid cancer	0.00178	0.0295	CbGpPWpGaD
Aprepitant—TACR1—SIDS Susceptibility Pathways—RET—thyroid cancer	0.00156	0.0259	CbGpPWpGaD
Aprepitant—TACR1—SIDS Susceptibility Pathways—THRB—thyroid cancer	0.00145	0.024	CbGpPWpGaD
Aprepitant—TACR3—Peptide ligand-binding receptors—SST—thyroid cancer	0.00133	0.0221	CbGpPWpGaD
Aprepitant—TACR1—Spinal Cord Injury—LGALS3—thyroid cancer	0.00122	0.0201	CbGpPWpGaD
Aprepitant—TACR3—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.00115	0.0191	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—CALCB—thyroid cancer	0.00107	0.0177	CbGpPWpGaD
Aprepitant—TACR3—Gastrin-CREB signalling pathway via PKC and MAPK—CDK1—thyroid cancer	0.00105	0.0174	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—CALCB—thyroid cancer	0.000971	0.0161	CbGpPWpGaD
Aprepitant—TACR1—SIDS Susceptibility Pathways—PRKAR1A—thyroid cancer	0.000965	0.016	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—CALCB—thyroid cancer	0.000924	0.0153	CbGpPWpGaD
Aprepitant—TACR3—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.000895	0.0148	CbGpPWpGaD
Aprepitant—TACR3—GPCR ligand binding—TSHR—thyroid cancer	0.000876	0.0145	CbGpPWpGaD
Aprepitant—CYP2C19—Arachidonic acid metabolism—HPGD—thyroid cancer	0.000851	0.0141	CbGpPWpGaD
Aprepitant—TACR1—Spinal Cord Injury—CDK1—thyroid cancer	0.000831	0.0138	CbGpPWpGaD
Aprepitant—CYP2C9—Arachidonic acid metabolism—HPGD—thyroid cancer	0.000776	0.0129	CbGpPWpGaD
Aprepitant—TACR1—SIDS Susceptibility Pathways—SST—thyroid cancer	0.000763	0.0126	CbGpPWpGaD
Aprepitant—TACR3—GPCR ligand binding—PTCH1—thyroid cancer	0.000745	0.0123	CbGpPWpGaD
Aprepitant—CYP3A7—Metapathway biotransformation—CHST14—thyroid cancer	0.000694	0.0115	CbGpPWpGaD
Aprepitant—TACR3—GPCR ligand binding—SST—thyroid cancer	0.000681	0.0113	CbGpPWpGaD
Aprepitant—CYP3A4—Liver X Receptor Pathway—RXRA—thyroid cancer	0.00067	0.0111	CbGpPWpGaD
Aprepitant—CYP1A2—Arachidonic acid metabolism—HPGD—thyroid cancer	0.000663	0.011	CbGpPWpGaD
Aprepitant—TACR3—GPCR ligand binding—CALCA—thyroid cancer	0.000656	0.0109	CbGpPWpGaD
Aprepitant—TACR1—Peptide ligand-binding receptors—SST—thyroid cancer	0.000652	0.0108	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—RET—thyroid cancer	0.000649	0.0107	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CALCB—thyroid cancer	0.000574	0.0095	CbGpPWpGaD
Aprepitant—CYP3A5—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000569	0.00942	CbGpPWpGaD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.000562	0.00931	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—TRIM33—thyroid cancer	0.000544	0.00901	CbGpPWpGaD
Aprepitant—Diabetes mellitus—Epirubicin—thyroid cancer	0.000531	0.00138	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00053	0.00138	CcSEcCtD
Aprepitant—Fatigue—Sorafenib—thyroid cancer	0.000529	0.00138	CcSEcCtD
Aprepitant—Photosensitivity—Epirubicin—thyroid cancer	0.000526	0.00137	CcSEcCtD
Aprepitant—Pain—Sorafenib—thyroid cancer	0.000525	0.00137	CcSEcCtD
Aprepitant—Constipation—Sorafenib—thyroid cancer	0.000525	0.00137	CcSEcCtD
Aprepitant—TACR1—GPCR downstream signaling—CALCB—thyroid cancer	0.000522	0.00865	CbGpPWpGaD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—CDK1—thyroid cancer	0.000514	0.00852	CbGpPWpGaD
Aprepitant—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000502	0.00131	CcSEcCtD
Aprepitant—CYP3A5—Metapathway biotransformation—CHST14—thyroid cancer	0.000502	0.00831	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—TSHR—thyroid cancer	0.000495	0.0082	CbGpPWpGaD
Aprepitant—Hot flush—Epirubicin—thyroid cancer	0.000493	0.00128	CcSEcCtD
Aprepitant—Thrombophlebitis—Doxorubicin—thyroid cancer	0.000493	0.00128	CcSEcCtD
Aprepitant—Blood alkaline phosphatase increased—Doxorubicin—thyroid cancer	0.000491	0.00128	CcSEcCtD
Aprepitant—Diabetes mellitus—Doxorubicin—thyroid cancer	0.000491	0.00128	CcSEcCtD
Aprepitant—Menopausal symptoms—Epirubicin—thyroid cancer	0.000489	0.00127	CcSEcCtD
Aprepitant—Urticaria—Sorafenib—thyroid cancer	0.000488	0.00127	CcSEcCtD
Aprepitant—Photosensitivity—Doxorubicin—thyroid cancer	0.000486	0.00126	CcSEcCtD
Aprepitant—Abdominal pain—Sorafenib—thyroid cancer	0.000485	0.00126	CcSEcCtD
Aprepitant—Body temperature increased—Sorafenib—thyroid cancer	0.000485	0.00126	CcSEcCtD
Aprepitant—Renal impairment—Epirubicin—thyroid cancer	0.000485	0.00126	CcSEcCtD
Aprepitant—CYP3A7—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000476	0.00788	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—CALCB—thyroid cancer	0.000474	0.00786	CbGpPWpGaD
Aprepitant—Lethargy—Epirubicin—thyroid cancer	0.000471	0.00122	CcSEcCtD
Aprepitant—Hyponatraemia—Epirubicin—thyroid cancer	0.000463	0.00121	CcSEcCtD
Aprepitant—Osteoarthritis—Epirubicin—thyroid cancer	0.000462	0.0012	CcSEcCtD
Aprepitant—TACR1—SIDS Susceptibility Pathways—HIF1A—thyroid cancer	0.000458	0.00759	CbGpPWpGaD
Aprepitant—Hot flush—Doxorubicin—thyroid cancer	0.000456	0.00119	CcSEcCtD
Aprepitant—Menopausal symptoms—Doxorubicin—thyroid cancer	0.000453	0.00118	CcSEcCtD
Aprepitant—Hypersensitivity—Sorafenib—thyroid cancer	0.000452	0.00118	CcSEcCtD
Aprepitant—TACR3—Signaling by GPCR—TSHR—thyroid cancer	0.00045	0.00745	CbGpPWpGaD
Aprepitant—Renal impairment—Doxorubicin—thyroid cancer	0.000449	0.00117	CcSEcCtD
Aprepitant—TACR3—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000442	0.00733	CbGpPWpGaD
Aprepitant—Asthenia—Sorafenib—thyroid cancer	0.00044	0.00115	CcSEcCtD
Aprepitant—CYP2C19—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.00044	0.00728	CbGpPWpGaD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.000437	0.00724	CbGpPWpGaD
Aprepitant—Lethargy—Doxorubicin—thyroid cancer	0.000436	0.00113	CcSEcCtD
Aprepitant—Pruritus—Sorafenib—thyroid cancer	0.000434	0.00113	CcSEcCtD
Aprepitant—Blood creatinine increased—Epirubicin—thyroid cancer	0.000432	0.00112	CcSEcCtD
Aprepitant—Dehydration—Epirubicin—thyroid cancer	0.000429	0.00112	CcSEcCtD
Aprepitant—Hyponatraemia—Doxorubicin—thyroid cancer	0.000429	0.00112	CcSEcCtD
Aprepitant—TACR1—GPCR ligand binding—TSHR—thyroid cancer	0.000428	0.00709	CbGpPWpGaD
Aprepitant—Osteoarthritis—Doxorubicin—thyroid cancer	0.000427	0.00111	CcSEcCtD
Aprepitant—Abdominal pain upper—Epirubicin—thyroid cancer	0.000422	0.0011	CcSEcCtD
Aprepitant—Hypokalaemia—Epirubicin—thyroid cancer	0.00042	0.00109	CcSEcCtD
Aprepitant—Diarrhoea—Sorafenib—thyroid cancer	0.00042	0.00109	CcSEcCtD
Aprepitant—Breast disorder—Epirubicin—thyroid cancer	0.000417	0.00108	CcSEcCtD
Aprepitant—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.000416	0.00108	CcSEcCtD
Aprepitant—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.000416	0.00108	CcSEcCtD
Aprepitant—Gastritis—Epirubicin—thyroid cancer	0.000408	0.00106	CcSEcCtD
Aprepitant—Muscular weakness—Epirubicin—thyroid cancer	0.000407	0.00106	CcSEcCtD
Aprepitant—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.000407	0.00106	CcSEcCtD
Aprepitant—Dizziness—Sorafenib—thyroid cancer	0.000406	0.00106	CcSEcCtD
Aprepitant—Abdominal distension—Epirubicin—thyroid cancer	0.000402	0.00104	CcSEcCtD
Aprepitant—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.000401	0.00664	CbGpPWpGaD
Aprepitant—CYP2C9—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000401	0.00664	CbGpPWpGaD
Aprepitant—Blood creatinine increased—Doxorubicin—thyroid cancer	0.0004	0.00104	CcSEcCtD
Aprepitant—Dysphagia—Epirubicin—thyroid cancer	0.000399	0.00104	CcSEcCtD
Aprepitant—Dehydration—Doxorubicin—thyroid cancer	0.000397	0.00103	CcSEcCtD
Aprepitant—Vomiting—Sorafenib—thyroid cancer	0.00039	0.00101	CcSEcCtD
Aprepitant—Abdominal pain upper—Doxorubicin—thyroid cancer	0.00039	0.00101	CcSEcCtD
Aprepitant—Hypokalaemia—Doxorubicin—thyroid cancer	0.000389	0.00101	CcSEcCtD
Aprepitant—CYP2C19—Metapathway biotransformation—CHST14—thyroid cancer	0.000388	0.00642	CbGpPWpGaD
Aprepitant—Rash—Sorafenib—thyroid cancer	0.000387	0.00101	CcSEcCtD
Aprepitant—Dermatitis—Sorafenib—thyroid cancer	0.000387	0.00101	CcSEcCtD
Aprepitant—Breast disorder—Doxorubicin—thyroid cancer	0.000386	0.001	CcSEcCtD
Aprepitant—CYP3A7—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000386	0.00639	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—SST—thyroid cancer	0.000385	0.00638	CbGpPWpGaD
Aprepitant—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.000385	0.001	CcSEcCtD
Aprepitant—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.000385	0.001	CcSEcCtD
Aprepitant—Headache—Sorafenib—thyroid cancer	0.000385	0.001	CcSEcCtD
Aprepitant—TACR1—Spinal Cord Injury—PTGS2—thyroid cancer	0.000383	0.00634	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—PTCH1—thyroid cancer	0.000382	0.00633	CbGpPWpGaD
Aprepitant—Gastritis—Doxorubicin—thyroid cancer	0.000378	0.000983	CcSEcCtD
Aprepitant—TACR3—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	0.000378	0.00626	CbGpPWpGaD
Aprepitant—Muscular weakness—Doxorubicin—thyroid cancer	0.000377	0.00098	CcSEcCtD
Aprepitant—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.000377	0.00098	CcSEcCtD
Aprepitant—Dysuria—Epirubicin—thyroid cancer	0.000373	0.00097	CcSEcCtD
Aprepitant—Neutropenia—Epirubicin—thyroid cancer	0.000373	0.00097	CcSEcCtD
Aprepitant—Abdominal distension—Doxorubicin—thyroid cancer	0.000372	0.000966	CcSEcCtD
Aprepitant—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.000371	0.000964	CcSEcCtD
Aprepitant—TACR3—GPCR downstream signaling—CALCA—thyroid cancer	0.000371	0.00614	CbGpPWpGaD
Aprepitant—Dysphagia—Doxorubicin—thyroid cancer	0.000369	0.00096	CcSEcCtD
Aprepitant—Pollakiuria—Epirubicin—thyroid cancer	0.000368	0.000958	CcSEcCtD
Aprepitant—Nausea—Sorafenib—thyroid cancer	0.000365	0.000948	CcSEcCtD
Aprepitant—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000364	0.000947	CcSEcCtD
Aprepitant—TACR1—GPCR ligand binding—PTCH1—thyroid cancer	0.000364	0.00603	CbGpPWpGaD
Aprepitant—Weight increased—Epirubicin—thyroid cancer	0.000363	0.000944	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—TCF7L1—thyroid cancer	0.000363	0.00601	CbGpPWpGaD
Aprepitant—Weight decreased—Epirubicin—thyroid cancer	0.000361	0.000939	CcSEcCtD
Aprepitant—Hyperglycaemia—Epirubicin—thyroid cancer	0.00036	0.000936	CcSEcCtD
Aprepitant—Pneumonia—Epirubicin—thyroid cancer	0.000358	0.00093	CcSEcCtD
Aprepitant—Infestation NOS—Epirubicin—thyroid cancer	0.000356	0.000925	CcSEcCtD
Aprepitant—Infestation—Epirubicin—thyroid cancer	0.000356	0.000925	CcSEcCtD
Aprepitant—CYP2C9—Metapathway biotransformation—CHST14—thyroid cancer	0.000354	0.00586	CbGpPWpGaD
Aprepitant—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.000353	0.000917	CcSEcCtD
Aprepitant—TACR3—Signaling by GPCR—SST—thyroid cancer	0.00035	0.00579	CbGpPWpGaD
Aprepitant—Renal failure—Epirubicin—thyroid cancer	0.00035	0.000909	CcSEcCtD
Aprepitant—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000349	0.000907	CcSEcCtD
Aprepitant—Stomatitis—Epirubicin—thyroid cancer	0.000347	0.000902	CcSEcCtD
Aprepitant—TACR1—Spinal Cord Injury—CCND1—thyroid cancer	0.000346	0.00573	CbGpPWpGaD
Aprepitant—Urinary tract infection—Epirubicin—thyroid cancer	0.000346	0.000899	CcSEcCtD
Aprepitant—Conjunctivitis—Epirubicin—thyroid cancer	0.000346	0.000899	CcSEcCtD
Aprepitant—Neutropenia—Doxorubicin—thyroid cancer	0.000345	0.000898	CcSEcCtD
Aprepitant—Dysuria—Doxorubicin—thyroid cancer	0.000345	0.000898	CcSEcCtD
Aprepitant—CYP3A5—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000344	0.00569	CbGpPWpGaD
Aprepitant—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.000343	0.000892	CcSEcCtD
Aprepitant—Pollakiuria—Doxorubicin—thyroid cancer	0.000341	0.000887	CcSEcCtD
Aprepitant—Haematuria—Epirubicin—thyroid cancer	0.000339	0.000882	CcSEcCtD
Aprepitant—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.000337	0.000876	CcSEcCtD
Aprepitant—TACR3—Signaling by GPCR—CALCA—thyroid cancer	0.000337	0.00557	CbGpPWpGaD
Aprepitant—Weight increased—Doxorubicin—thyroid cancer	0.000336	0.000874	CcSEcCtD
Aprepitant—Weight decreased—Doxorubicin—thyroid cancer	0.000334	0.000868	CcSEcCtD
Aprepitant—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000333	0.000866	CcSEcCtD
Aprepitant—TACR1—GPCR ligand binding—SST—thyroid cancer	0.000333	0.00551	CbGpPWpGaD
Aprepitant—Pneumonia—Doxorubicin—thyroid cancer	0.000331	0.000861	CcSEcCtD
Aprepitant—Infestation—Doxorubicin—thyroid cancer	0.000329	0.000856	CcSEcCtD
Aprepitant—Infestation NOS—Doxorubicin—thyroid cancer	0.000329	0.000856	CcSEcCtD
Aprepitant—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000326	0.000849	CcSEcCtD
Aprepitant—TACR3—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	0.000325	0.00538	CbGpPWpGaD
Aprepitant—Bradycardia—Epirubicin—thyroid cancer	0.000325	0.000845	CcSEcCtD
Aprepitant—Renal failure—Doxorubicin—thyroid cancer	0.000323	0.000841	CcSEcCtD
Aprepitant—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000323	0.000839	CcSEcCtD
Aprepitant—Stomatitis—Doxorubicin—thyroid cancer	0.000321	0.000834	CcSEcCtD
Aprepitant—TACR1—GPCR ligand binding—CALCA—thyroid cancer	0.00032	0.00531	CbGpPWpGaD
Aprepitant—Urinary tract infection—Doxorubicin—thyroid cancer	0.00032	0.000832	CcSEcCtD
Aprepitant—Conjunctivitis—Doxorubicin—thyroid cancer	0.00032	0.000832	CcSEcCtD
Aprepitant—Hypoaesthesia—Epirubicin—thyroid cancer	0.000318	0.000826	CcSEcCtD
Aprepitant—Pharyngitis—Epirubicin—thyroid cancer	0.000317	0.000824	CcSEcCtD
Aprepitant—Urinary tract disorder—Epirubicin—thyroid cancer	0.000315	0.00082	CcSEcCtD
Aprepitant—Haematuria—Doxorubicin—thyroid cancer	0.000314	0.000816	CcSEcCtD
Aprepitant—Connective tissue disorder—Epirubicin—thyroid cancer	0.000314	0.000816	CcSEcCtD
Aprepitant—Urethral disorder—Epirubicin—thyroid cancer	0.000313	0.000814	CcSEcCtD
Aprepitant—TACR3—Signaling by GPCR—CDK1—thyroid cancer	0.000305	0.00505	CbGpPWpGaD
Aprepitant—CYP1A2—Metapathway biotransformation—CHST14—thyroid cancer	0.000302	0.005	CbGpPWpGaD
Aprepitant—Erythema multiforme—Epirubicin—thyroid cancer	0.000302	0.000785	CcSEcCtD
Aprepitant—Bradycardia—Doxorubicin—thyroid cancer	0.000301	0.000782	CcSEcCtD
Aprepitant—Eye disorder—Epirubicin—thyroid cancer	0.000298	0.000776	CcSEcCtD
Aprepitant—Tinnitus—Epirubicin—thyroid cancer	0.000298	0.000774	CcSEcCtD
Aprepitant—Cardiac disorder—Epirubicin—thyroid cancer	0.000296	0.000771	CcSEcCtD
Aprepitant—Flushing—Epirubicin—thyroid cancer	0.000296	0.000771	CcSEcCtD
Aprepitant—Hypoaesthesia—Doxorubicin—thyroid cancer	0.000294	0.000764	CcSEcCtD
Aprepitant—Pharyngitis—Doxorubicin—thyroid cancer	0.000293	0.000763	CcSEcCtD
Aprepitant—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000292	0.000759	CcSEcCtD
Aprepitant—Connective tissue disorder—Doxorubicin—thyroid cancer	0.00029	0.000755	CcSEcCtD
Aprepitant—Angiopathy—Epirubicin—thyroid cancer	0.00029	0.000753	CcSEcCtD
Aprepitant—Urethral disorder—Doxorubicin—thyroid cancer	0.00029	0.000753	CcSEcCtD
Aprepitant—Immune system disorder—Epirubicin—thyroid cancer	0.000288	0.00075	CcSEcCtD
Aprepitant—Mediastinal disorder—Epirubicin—thyroid cancer	0.000288	0.000748	CcSEcCtD
Aprepitant—Chills—Epirubicin—thyroid cancer	0.000286	0.000745	CcSEcCtD
Aprepitant—Alopecia—Epirubicin—thyroid cancer	0.000282	0.000734	CcSEcCtD
Aprepitant—TACR1—Signaling Pathways—CALCB—thyroid cancer	0.00028	0.00464	CbGpPWpGaD
Aprepitant—Mental disorder—Epirubicin—thyroid cancer	0.00028	0.000727	CcSEcCtD
Aprepitant—Erythema multiforme—Doxorubicin—thyroid cancer	0.000279	0.000726	CcSEcCtD
Aprepitant—CYP3A5—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000279	0.00462	CbGpPWpGaD
Aprepitant—Erythema—Epirubicin—thyroid cancer	0.000278	0.000723	CcSEcCtD
Aprepitant—Malnutrition—Epirubicin—thyroid cancer	0.000278	0.000723	CcSEcCtD
Aprepitant—TACR3—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	0.000276	0.00458	CbGpPWpGaD
Aprepitant—Eye disorder—Doxorubicin—thyroid cancer	0.000276	0.000718	CcSEcCtD
Aprepitant—Tinnitus—Doxorubicin—thyroid cancer	0.000275	0.000716	CcSEcCtD
Aprepitant—Flushing—Doxorubicin—thyroid cancer	0.000274	0.000713	CcSEcCtD
Aprepitant—Cardiac disorder—Doxorubicin—thyroid cancer	0.000274	0.000713	CcSEcCtD
Aprepitant—Flatulence—Epirubicin—thyroid cancer	0.000274	0.000712	CcSEcCtD
Aprepitant—Dysgeusia—Epirubicin—thyroid cancer	0.000272	0.000708	CcSEcCtD
Aprepitant—Back pain—Epirubicin—thyroid cancer	0.000269	0.000699	CcSEcCtD
Aprepitant—Angiopathy—Doxorubicin—thyroid cancer	0.000268	0.000697	CcSEcCtD
Aprepitant—Muscle spasms—Epirubicin—thyroid cancer	0.000267	0.000695	CcSEcCtD
Aprepitant—Immune system disorder—Doxorubicin—thyroid cancer	0.000267	0.000694	CcSEcCtD
Aprepitant—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000266	0.000692	CcSEcCtD
Aprepitant—CYP2C19—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000266	0.0044	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—TRIM33—thyroid cancer	0.000266	0.0044	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—TSHR—thyroid cancer	0.000266	0.0044	CbGpPWpGaD
Aprepitant—Chills—Doxorubicin—thyroid cancer	0.000265	0.000689	CcSEcCtD
Aprepitant—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000264	0.00438	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—PRKAR1A—thyroid cancer	0.000261	0.00433	CbGpPWpGaD
Aprepitant—Alopecia—Doxorubicin—thyroid cancer	0.000261	0.000679	CcSEcCtD
Aprepitant—Mental disorder—Doxorubicin—thyroid cancer	0.000259	0.000673	CcSEcCtD
Aprepitant—Ill-defined disorder—Epirubicin—thyroid cancer	0.000258	0.000671	CcSEcCtD
Aprepitant—Erythema—Doxorubicin—thyroid cancer	0.000257	0.000669	CcSEcCtD
Aprepitant—Malnutrition—Doxorubicin—thyroid cancer	0.000257	0.000669	CcSEcCtD
Aprepitant—Anaemia—Epirubicin—thyroid cancer	0.000257	0.000668	CcSEcCtD
Aprepitant—Flatulence—Doxorubicin—thyroid cancer	0.000253	0.000659	CcSEcCtD
Aprepitant—Dysgeusia—Doxorubicin—thyroid cancer	0.000252	0.000655	CcSEcCtD
Aprepitant—Malaise—Epirubicin—thyroid cancer	0.000251	0.000652	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—MEN1—thyroid cancer	0.00025	0.00414	CbGpPWpGaD
Aprepitant—Syncope—Epirubicin—thyroid cancer	0.000249	0.000648	CcSEcCtD
Aprepitant—Back pain—Doxorubicin—thyroid cancer	0.000249	0.000647	CcSEcCtD
Aprepitant—Muscle spasms—Doxorubicin—thyroid cancer	0.000247	0.000643	CcSEcCtD
Aprepitant—Palpitations—Epirubicin—thyroid cancer	0.000246	0.000639	CcSEcCtD
Aprepitant—Loss of consciousness—Epirubicin—thyroid cancer	0.000244	0.000635	CcSEcCtD
Aprepitant—Cough—Epirubicin—thyroid cancer	0.000243	0.000631	CcSEcCtD
Aprepitant—CYP2C9—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000242	0.00401	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—TSHR—thyroid cancer	0.000242	0.004	CbGpPWpGaD
Aprepitant—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000241	0.00399	CbGpPWpGaD
Aprepitant—Convulsion—Epirubicin—thyroid cancer	0.000241	0.000626	CcSEcCtD
Aprepitant—Hypertension—Epirubicin—thyroid cancer	0.00024	0.000624	CcSEcCtD
Aprepitant—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000239	0.000621	CcSEcCtD
Aprepitant—Anaemia—Doxorubicin—thyroid cancer	0.000238	0.000618	CcSEcCtD
Aprepitant—Arthralgia—Epirubicin—thyroid cancer	0.000237	0.000615	CcSEcCtD
Aprepitant—Myalgia—Epirubicin—thyroid cancer	0.000237	0.000615	CcSEcCtD
Aprepitant—Chest pain—Epirubicin—thyroid cancer	0.000237	0.000615	CcSEcCtD
Aprepitant—Anxiety—Epirubicin—thyroid cancer	0.000236	0.000613	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000235	0.000611	CcSEcCtD
Aprepitant—Discomfort—Epirubicin—thyroid cancer	0.000234	0.000608	CcSEcCtD
Aprepitant—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.000233	0.00386	CbGpPWpGaD
Aprepitant—Malaise—Doxorubicin—thyroid cancer	0.000232	0.000603	CcSEcCtD
Aprepitant—Dry mouth—Epirubicin—thyroid cancer	0.000231	0.000602	CcSEcCtD
Aprepitant—Syncope—Doxorubicin—thyroid cancer	0.000231	0.0006	CcSEcCtD
Aprepitant—Confusional state—Epirubicin—thyroid cancer	0.000229	0.000595	CcSEcCtD
Aprepitant—TACR1—Spinal Cord Injury—TP53—thyroid cancer	0.000228	0.00378	CbGpPWpGaD
Aprepitant—Palpitations—Doxorubicin—thyroid cancer	0.000227	0.000591	CcSEcCtD
Aprepitant—Anaphylactic shock—Epirubicin—thyroid cancer	0.000227	0.00059	CcSEcCtD
Aprepitant—Oedema—Epirubicin—thyroid cancer	0.000227	0.00059	CcSEcCtD
Aprepitant—Loss of consciousness—Doxorubicin—thyroid cancer	0.000226	0.000588	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—PTCH1—thyroid cancer	0.000226	0.00374	CbGpPWpGaD
Aprepitant—Infection—Epirubicin—thyroid cancer	0.000225	0.000586	CcSEcCtD
Aprepitant—Cough—Doxorubicin—thyroid cancer	0.000224	0.000584	CcSEcCtD
Aprepitant—Shock—Epirubicin—thyroid cancer	0.000223	0.00058	CcSEcCtD
Aprepitant—Convulsion—Doxorubicin—thyroid cancer	0.000223	0.00058	CcSEcCtD
Aprepitant—Nervous system disorder—Epirubicin—thyroid cancer	0.000222	0.000579	CcSEcCtD
Aprepitant—Thrombocytopenia—Epirubicin—thyroid cancer	0.000222	0.000578	CcSEcCtD
Aprepitant—Hypertension—Doxorubicin—thyroid cancer	0.000222	0.000577	CcSEcCtD
Aprepitant—Tachycardia—Epirubicin—thyroid cancer	0.000221	0.000576	CcSEcCtD
Aprepitant—Skin disorder—Epirubicin—thyroid cancer	0.00022	0.000573	CcSEcCtD
Aprepitant—TACR1—Signaling by GPCR—TSHR—thyroid cancer	0.00022	0.00364	CbGpPWpGaD
Aprepitant—Hyperhidrosis—Epirubicin—thyroid cancer	0.000219	0.00057	CcSEcCtD
Aprepitant—Chest pain—Doxorubicin—thyroid cancer	0.000219	0.000569	CcSEcCtD
Aprepitant—Arthralgia—Doxorubicin—thyroid cancer	0.000219	0.000569	CcSEcCtD
Aprepitant—Myalgia—Doxorubicin—thyroid cancer	0.000219	0.000569	CcSEcCtD
Aprepitant—Anxiety—Doxorubicin—thyroid cancer	0.000218	0.000567	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000217	0.000566	CcSEcCtD
Aprepitant—Discomfort—Doxorubicin—thyroid cancer	0.000216	0.000563	CcSEcCtD
Aprepitant—Anorexia—Epirubicin—thyroid cancer	0.000216	0.000562	CcSEcCtD
Aprepitant—TACR1—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000216	0.00358	CbGpPWpGaD
Aprepitant—CYP2C19—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000216	0.00357	CbGpPWpGaD
Aprepitant—Dry mouth—Doxorubicin—thyroid cancer	0.000214	0.000557	CcSEcCtD
Aprepitant—Hypotension—Epirubicin—thyroid cancer	0.000212	0.000551	CcSEcCtD
Aprepitant—Confusional state—Doxorubicin—thyroid cancer	0.000212	0.00055	CcSEcCtD
Aprepitant—Anaphylactic shock—Doxorubicin—thyroid cancer	0.00021	0.000546	CcSEcCtD
Aprepitant—Oedema—Doxorubicin—thyroid cancer	0.00021	0.000546	CcSEcCtD
Aprepitant—Infection—Doxorubicin—thyroid cancer	0.000209	0.000542	CcSEcCtD
Aprepitant—CYP1A2—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000207	0.00343	CbGpPWpGaD
Aprepitant—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000207	0.000537	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—SST—thyroid cancer	0.000207	0.00342	CbGpPWpGaD
Aprepitant—Shock—Doxorubicin—thyroid cancer	0.000206	0.000537	CcSEcCtD
Aprepitant—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000206	0.00341	CbGpPWpGaD
Aprepitant—Nervous system disorder—Doxorubicin—thyroid cancer	0.000206	0.000535	CcSEcCtD
Aprepitant—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000205	0.000534	CcSEcCtD
Aprepitant—Insomnia—Epirubicin—thyroid cancer	0.000205	0.000534	CcSEcCtD
Aprepitant—CYP3A7—Biological oxidations—RXRA—thyroid cancer	0.000205	0.00339	CbGpPWpGaD
Aprepitant—Tachycardia—Doxorubicin—thyroid cancer	0.000205	0.000533	CcSEcCtD
Aprepitant—Skin disorder—Doxorubicin—thyroid cancer	0.000204	0.00053	CcSEcCtD
Aprepitant—Paraesthesia—Epirubicin—thyroid cancer	0.000204	0.00053	CcSEcCtD
Aprepitant—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000203	0.000528	CcSEcCtD
Aprepitant—Dyspnoea—Epirubicin—thyroid cancer	0.000202	0.000526	CcSEcCtD
Aprepitant—Somnolence—Epirubicin—thyroid cancer	0.000202	0.000524	CcSEcCtD
Aprepitant—Anorexia—Doxorubicin—thyroid cancer	0.0002	0.00052	CcSEcCtD
Aprepitant—Dyspepsia—Epirubicin—thyroid cancer	0.0002	0.000519	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—CALCA—thyroid cancer	0.000199	0.00329	CbGpPWpGaD
Aprepitant—Decreased appetite—Epirubicin—thyroid cancer	0.000197	0.000513	CcSEcCtD
Aprepitant—CYP2C9—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000197	0.00325	CbGpPWpGaD
Aprepitant—Hypotension—Doxorubicin—thyroid cancer	0.000196	0.00051	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000196	0.000509	CcSEcCtD
Aprepitant—Fatigue—Epirubicin—thyroid cancer	0.000196	0.000509	CcSEcCtD
Aprepitant—Constipation—Epirubicin—thyroid cancer	0.000194	0.000504	CcSEcCtD
Aprepitant—Pain—Epirubicin—thyroid cancer	0.000194	0.000504	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000191	0.000497	CcSEcCtD
Aprepitant—Insomnia—Doxorubicin—thyroid cancer	0.00019	0.000494	CcSEcCtD
Aprepitant—Paraesthesia—Doxorubicin—thyroid cancer	0.000188	0.00049	CcSEcCtD
Aprepitant—TACR1—GPCR downstream signaling—SST—thyroid cancer	0.000188	0.00311	CbGpPWpGaD
Aprepitant—Dyspnoea—Doxorubicin—thyroid cancer	0.000187	0.000487	CcSEcCtD
Aprepitant—Feeling abnormal—Epirubicin—thyroid cancer	0.000187	0.000486	CcSEcCtD
Aprepitant—TACR1—Signaling by GPCR—PTCH1—thyroid cancer	0.000187	0.00309	CbGpPWpGaD
Aprepitant—Somnolence—Doxorubicin—thyroid cancer	0.000187	0.000485	CcSEcCtD
Aprepitant—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000185	0.000482	CcSEcCtD
Aprepitant—Dyspepsia—Doxorubicin—thyroid cancer	0.000185	0.000481	CcSEcCtD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	0.000184	0.00305	CbGpPWpGaD
Aprepitant—Decreased appetite—Doxorubicin—thyroid cancer	0.000182	0.000475	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000181	0.000471	CcSEcCtD
Aprepitant—TACR1—GPCR downstream signaling—CALCA—thyroid cancer	0.000181	0.003	CbGpPWpGaD
Aprepitant—Fatigue—Doxorubicin—thyroid cancer	0.000181	0.000471	CcSEcCtD
Aprepitant—Urticaria—Epirubicin—thyroid cancer	0.00018	0.000469	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—CDK1—thyroid cancer	0.00018	0.00298	CbGpPWpGaD
Aprepitant—Pain—Doxorubicin—thyroid cancer	0.000179	0.000467	CcSEcCtD
Aprepitant—Constipation—Doxorubicin—thyroid cancer	0.000179	0.000467	CcSEcCtD
Aprepitant—Abdominal pain—Epirubicin—thyroid cancer	0.000179	0.000466	CcSEcCtD
Aprepitant—Body temperature increased—Epirubicin—thyroid cancer	0.000179	0.000466	CcSEcCtD
Aprepitant—TACR1—Signaling Pathways—TCF7L1—thyroid cancer	0.000177	0.00294	CbGpPWpGaD
Aprepitant—Feeling abnormal—Doxorubicin—thyroid cancer	0.000173	0.00045	CcSEcCtD
Aprepitant—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000172	0.000446	CcSEcCtD
Aprepitant—TACR1—Signaling by GPCR—SST—thyroid cancer	0.000171	0.00283	CbGpPWpGaD
Aprepitant—CYP1A2—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000168	0.00278	CbGpPWpGaD
Aprepitant—Hypersensitivity—Epirubicin—thyroid cancer	0.000167	0.000435	CcSEcCtD
Aprepitant—Urticaria—Doxorubicin—thyroid cancer	0.000167	0.000434	CcSEcCtD
Aprepitant—Abdominal pain—Doxorubicin—thyroid cancer	0.000166	0.000432	CcSEcCtD
Aprepitant—Body temperature increased—Doxorubicin—thyroid cancer	0.000166	0.000432	CcSEcCtD
Aprepitant—TACR1—Signaling by GPCR—CALCA—thyroid cancer	0.000164	0.00272	CbGpPWpGaD
Aprepitant—Asthenia—Epirubicin—thyroid cancer	0.000163	0.000423	CcSEcCtD
Aprepitant—Pruritus—Epirubicin—thyroid cancer	0.00016	0.000417	CcSEcCtD
Aprepitant—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.00016	0.00265	CbGpPWpGaD
Aprepitant—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000159	0.00263	CbGpPWpGaD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	0.000159	0.00263	CbGpPWpGaD
Aprepitant—Diarrhoea—Epirubicin—thyroid cancer	0.000155	0.000404	CcSEcCtD
Aprepitant—Hypersensitivity—Doxorubicin—thyroid cancer	0.000155	0.000402	CcSEcCtD
Aprepitant—CYP2C19—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000153	0.00253	CbGpPWpGaD
Aprepitant—Asthenia—Doxorubicin—thyroid cancer	0.000151	0.000392	CcSEcCtD
Aprepitant—CYP3A7—Metabolism—MINPP1—thyroid cancer	0.00015	0.00249	CbGpPWpGaD
Aprepitant—Dizziness—Epirubicin—thyroid cancer	0.00015	0.00039	CcSEcCtD
Aprepitant—TACR1—Signaling by GPCR—CDK1—thyroid cancer	0.000149	0.00246	CbGpPWpGaD
Aprepitant—Pruritus—Doxorubicin—thyroid cancer	0.000148	0.000386	CcSEcCtD
Aprepitant—CYP3A5—Biological oxidations—RXRA—thyroid cancer	0.000148	0.00245	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—NRG1—thyroid cancer	0.000144	0.00239	CbGpPWpGaD
Aprepitant—Vomiting—Epirubicin—thyroid cancer	0.000144	0.000375	CcSEcCtD
Aprepitant—Diarrhoea—Doxorubicin—thyroid cancer	0.000144	0.000373	CcSEcCtD
Aprepitant—Rash—Epirubicin—thyroid cancer	0.000143	0.000372	CcSEcCtD
Aprepitant—Dermatitis—Epirubicin—thyroid cancer	0.000143	0.000372	CcSEcCtD
Aprepitant—Headache—Epirubicin—thyroid cancer	0.000142	0.00037	CcSEcCtD
Aprepitant—CYP2C9—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000139	0.00231	CbGpPWpGaD
Aprepitant—Dizziness—Doxorubicin—thyroid cancer	0.000139	0.000361	CcSEcCtD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	0.000135	0.00223	CbGpPWpGaD
Aprepitant—Nausea—Epirubicin—thyroid cancer	0.000135	0.00035	CcSEcCtD
Aprepitant—Vomiting—Doxorubicin—thyroid cancer	0.000133	0.000347	CcSEcCtD
Aprepitant—Rash—Doxorubicin—thyroid cancer	0.000132	0.000344	CcSEcCtD
Aprepitant—Dermatitis—Doxorubicin—thyroid cancer	0.000132	0.000344	CcSEcCtD
Aprepitant—Headache—Doxorubicin—thyroid cancer	0.000131	0.000342	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—TERT—thyroid cancer	0.00013	0.00215	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—TSHR—thyroid cancer	0.00013	0.00215	CbGpPWpGaD
Aprepitant—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.00013	0.00215	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—NDUFA13—thyroid cancer	0.000128	0.00212	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—PRKAR1A—thyroid cancer	0.000128	0.00211	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—thyroid cancer	0.000127	0.00211	CbGpPWpGaD
Aprepitant—Nausea—Doxorubicin—thyroid cancer	0.000125	0.000324	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—HIF1A—thyroid cancer	0.000124	0.00205	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—MEN1—thyroid cancer	0.000122	0.00202	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000122	0.00202	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—CHST14—thyroid cancer	0.00012	0.00199	CbGpPWpGaD
Aprepitant—CYP1A2—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000119	0.00197	CbGpPWpGaD
Aprepitant—CYP2C19—Biological oxidations—RXRA—thyroid cancer	0.000114	0.0019	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000111	0.00184	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—PTCH1—thyroid cancer	0.00011	0.00183	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—NRAS—thyroid cancer	0.000109	0.00181	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—MINPP1—thyroid cancer	0.000109	0.0018	CbGpPWpGaD
Aprepitant—CYP2C9—Biological oxidations—RXRA—thyroid cancer	0.000104	0.00173	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—BRAF—thyroid cancer	0.000103	0.0017	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—SST—thyroid cancer	0.000101	0.00167	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	9.9e-05	0.00164	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CALCA—thyroid cancer	9.71e-05	0.00161	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—HPGD—thyroid cancer	9.7e-05	0.00161	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	9.48e-05	0.00157	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—KRAS—thyroid cancer	9.41e-05	0.00156	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—NDUFA13—thyroid cancer	9.25e-05	0.00153	CbGpPWpGaD
Aprepitant—CYP1A2—Biological oxidations—RXRA—thyroid cancer	8.92e-05	0.00148	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CDK1—thyroid cancer	8.79e-05	0.00146	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—CHST14—thyroid cancer	8.7e-05	0.00144	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	8.52e-05	0.00141	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—MINPP1—thyroid cancer	8.41e-05	0.00139	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—HRAS—thyroid cancer	8e-05	0.00132	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—AKT1—thyroid cancer	7.78e-05	0.00129	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—MINPP1—thyroid cancer	7.67e-05	0.00127	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CCND1—thyroid cancer	7.5e-05	0.00124	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	7.24e-05	0.0012	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—PTEN—thyroid cancer	7.24e-05	0.0012	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—NDUFA13—thyroid cancer	7.15e-05	0.00118	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—AKT1—thyroid cancer	7.06e-05	0.00117	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—NRG1—thyroid cancer	7.06e-05	0.00117	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—HPGD—thyroid cancer	7.01e-05	0.00116	CbGpPWpGaD
Aprepitant—CYP3A4—Biological oxidations—RXRA—thyroid cancer	6.88e-05	0.00114	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CHST14—thyroid cancer	6.72e-05	0.00111	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—MINPP1—thyroid cancer	6.55e-05	0.00109	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—NDUFA13—thyroid cancer	6.52e-05	0.00108	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—NRAS—thyroid cancer	6.46e-05	0.00107	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—TERT—thyroid cancer	6.34e-05	0.00105	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CHST14—thyroid cancer	6.13e-05	0.00102	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—HIF1A—thyroid cancer	6.06e-05	0.001	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—NDUFA13—thyroid cancer	5.57e-05	0.000923	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—TPR—thyroid cancer	5.57e-05	0.000922	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—KRAS—thyroid cancer	5.56e-05	0.00092	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PRKAR1A—thyroid cancer	5.48e-05	0.000907	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—HPGD—thyroid cancer	5.42e-05	0.000898	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—NRAS—thyroid cancer	5.34e-05	0.000884	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CHST14—thyroid cancer	5.24e-05	0.000868	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—MINPP1—thyroid cancer	5.06e-05	0.000838	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—BRAF—thyroid cancer	5.02e-05	0.000831	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—HPGD—thyroid cancer	4.94e-05	0.000818	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—TP53—thyroid cancer	4.94e-05	0.000818	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—HRAS—thyroid cancer	4.72e-05	0.000782	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—KRAS—thyroid cancer	4.59e-05	0.000761	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	4.4e-05	0.000728	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—NDUFA13—thyroid cancer	4.3e-05	0.000712	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—HPGD—thyroid cancer	4.22e-05	0.000699	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—AKT1—thyroid cancer	4.17e-05	0.000691	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—SLC5A5—thyroid cancer	4.17e-05	0.000691	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CHST14—thyroid cancer	4.04e-05	0.00067	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—TPR—thyroid cancer	4.03e-05	0.000667	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	4.01e-05	0.000664	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PRKAR1A—thyroid cancer	3.96e-05	0.000656	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—HRAS—thyroid cancer	3.91e-05	0.000647	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—AKT1—thyroid cancer	3.8e-05	0.000629	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CCND1—thyroid cancer	3.66e-05	0.000606	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—PTEN—thyroid cancer	3.53e-05	0.000585	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—RXRA—thyroid cancer	3.5e-05	0.00058	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—AKT1—thyroid cancer	3.45e-05	0.000571	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	3.43e-05	0.000567	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—HPGD—thyroid cancer	3.26e-05	0.00054	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—NRAS—thyroid cancer	3.15e-05	0.000522	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—TPR—thyroid cancer	3.11e-05	0.000515	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PRKAR1A—thyroid cancer	3.06e-05	0.000507	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—SLC5A5—thyroid cancer	3.01e-05	0.000499	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—TPR—thyroid cancer	2.84e-05	0.00047	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	2.79e-05	0.000462	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.78e-05	0.00046	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—KRAS—thyroid cancer	2.71e-05	0.000449	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—RXRA—thyroid cancer	2.53e-05	0.000419	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.53e-05	0.000419	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—TPR—thyroid cancer	2.43e-05	0.000402	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—TP53—thyroid cancer	2.41e-05	0.000399	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PRKAR1A—thyroid cancer	2.39e-05	0.000395	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—SLC5A5—thyroid cancer	2.33e-05	0.000386	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—HRAS—thyroid cancer	2.31e-05	0.000382	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PPARG—thyroid cancer	2.21e-05	0.000366	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.18e-05	0.000362	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.16e-05	0.000358	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—SLC5A5—thyroid cancer	2.12e-05	0.000352	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—AKT1—thyroid cancer	2.04e-05	0.000337	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.99e-05	0.00033	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—RXRA—thyroid cancer	1.96e-05	0.000324	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.9e-05	0.000315	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—TPR—thyroid cancer	1.87e-05	0.00031	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	1.84e-05	0.000305	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—SLC5A5—thyroid cancer	1.82e-05	0.000301	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—RXRA—thyroid cancer	1.79e-05	0.000296	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PTGS2—thyroid cancer	1.74e-05	0.000288	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.74e-05	0.000288	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.7e-05	0.000282	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PPARG—thyroid cancer	1.6e-05	0.000265	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—RXRA—thyroid cancer	1.53e-05	0.000253	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PTEN—thyroid cancer	1.52e-05	0.000251	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.48e-05	0.000246	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—SLC5A5—thyroid cancer	1.4e-05	0.000232	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PTGS2—thyroid cancer	1.26e-05	0.000208	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PPARG—thyroid cancer	1.24e-05	0.000205	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—RXRA—thyroid cancer	1.18e-05	0.000195	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PPARG—thyroid cancer	1.13e-05	0.000187	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PTEN—thyroid cancer	1.1e-05	0.000182	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PTGS2—thyroid cancer	9.72e-06	0.000161	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PPARG—thyroid cancer	9.63e-06	0.00016	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PTGS2—thyroid cancer	8.87e-06	0.000147	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—AKT1—thyroid cancer	8.75e-06	0.000145	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PTEN—thyroid cancer	8.48e-06	0.00014	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PTEN—thyroid cancer	7.73e-06	0.000128	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PTGS2—thyroid cancer	7.58e-06	0.000125	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PPARG—thyroid cancer	7.43e-06	0.000123	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PTEN—thyroid cancer	6.61e-06	0.000109	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—AKT1—thyroid cancer	6.32e-06	0.000105	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PTGS2—thyroid cancer	5.85e-06	9.68e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PTEN—thyroid cancer	5.1e-06	8.45e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—AKT1—thyroid cancer	4.89e-06	8.09e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—AKT1—thyroid cancer	4.46e-06	7.38e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—AKT1—thyroid cancer	3.81e-06	6.31e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—AKT1—thyroid cancer	2.94e-06	4.87e-05	CbGpPWpGaD
